Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Published: 2016-05-16; DOI: 10.1016/S0140-6736(16)00380-9; PubMed: 27197690
Journal(s): The Lancet [curation]
Authors
Feedback
Source and documentation (at github)
Wikidata page